Leukaemia drug dispute results in lawsuit from US pharma giant

30-06-2022

Leukaemia drug dispute results in lawsuit from US pharma giant

Bristol-Myers Squibb has filed a patent infringement lawsuit against Xspray Pharma over its plan to produce a generic version of the blockbuster drug sprycel (dasatinib).


BMS, generic, Hatch-Waxman Act, Xspray, Big pharma

LSIPR